多柔比星是臨床治療中有效的抗腫瘤藥，但其嚴(yán)重的心臟、肝臟毒性使其臨床應(yīng)用受到了極大限制。小檗堿是從黃連屬植物分得的生物堿，具有多種生物活性和藥理作用，對(duì)痢疾、真菌感染、糖尿病、腫瘤等都有治療作用。研究發(fā)現(xiàn)小檗堿不僅可以通過(guò)誘導(dǎo)腫瘤細(xì)胞的凋亡來(lái)增強(qiáng)多柔比星的抗腫瘤活性；還可以通過(guò)改變多柔比星引起心肌病的相關(guān)指標(biāo)來(lái)降低多柔比星引起的心肌細(xì)胞的損傷；另外，小檗堿對(duì)多柔比星引起的肝臟損傷也有一定的保護(hù)作用。綜述了小檗堿對(duì)多柔比星的增效減毒作用及其機(jī)制的研究進(jìn)展，這種發(fā)現(xiàn)提供了一種新穎的治療方法，對(duì)多柔比星臨床治療的發(fā)展具有重要的意義。

Doxorubicin is frequently used in chemotherapy due to its potent anticancer efficacy. However, the clinical use of doxorubicin has been largely restricted because of its cumulative cardiotoxicity and hepatotoxicity. Berberine is a botanical alkaloid purified from Coptis Salisb. Increasing studies reveal that berberine possesses a broad spectrum of bioactivity and pharmacological actions, including antidiarrheal, antifungal, antidiabetic, and antitumor effects. Currently researches have shown that berberine could induce the apoptosis of tumor cells so as to enhance doxorubicin antitumor activity. Furthermore, berberine attenuates doxorubicin- induced cardiac myocyte apoptosis. In addition, berberine could decrease the hepatotoxicity caused by doxorubicin. The synergistic attenuation and its mechanism of berberine on doxorubicin are reported currently in this paper. These findings offer a novel therapeutic method, and have clinical significance of doxorubicin treatment.